Real-world safety monitoring of Beyfortus (nirsevimab) in Korean infants and toddlers
Official title: A Prospective, Single-arm, Non-interventional, Multi-center, Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
Run by Sanofi · NCT07200206 · Data updated 2026-11-12
This program follows children up to 24 months in Korea who receive Beyfortus to see if the medicine is safe when used in routine care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Days to 24 Months |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Sanofi Industry-sponsored |
| Locations | 1 site (Hwaseong-si, Gyeonggi-do) |
| Status | Recruiting |
| Started | October 2, 2025 |
| Main results expected | September 26, 2029 |
| Study ends | September 26, 2029 |
| Registry record updated | December 3, 2025 |
| Trial ID | NCT07200206 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children in Korea up to 24 months of age who receive Beyfortus according to the approved indication and whose parent or legal representative provides informed consent.
✕Probably not a fit
Children with label contraindications, those enrolled in another interventional study within four weeks, or those older than 24 months are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This post-marketing surveillance follows children up to 24 months who receive Beyfortus in routine clinical practice in the Republic of Korea. Investigators enroll infants given the approved dose per the local product label and obtain parental informed consent, then monitor participants for 180 days after administration for adverse events and other safety outcomes. Participants with contraindications per the product label or those enrolled in another clinical investigation within four weeks are excluded. Data are collected from clinical visits and routine care records to characterize safety in a real-world setting.
Why it matters
Potential benefit: If successful, the surveillance could confirm Beyfortus's real-world safety in Korean children and increase clinician and parent confidence in its use.
How similar studies have gone: Randomized trials of nirsevimab have demonstrated reduced RSV lower respiratory tract infection in infants, and post-marketing safety monitoring is commonly performed to confirm findings in routine care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children up to 24 months of age who received Beyfortus according to the approved indications. * Informed consent signed by the parents / legally accepted representatives (LARs) of the participant. Exclusion Criteria: * Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device or a medical procedure. * Any contraindications according to the approved local product label of Beyfortus.
Where it's running
-
Nam Seung Woo Pediatric: 4100007
Hwaseong-si, Gyeonggi-do, South Korea Recruiting
Study contacts
- Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
- Email: Contact-US@sanofi.com
- Phone: 800-633-1610
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
RSV+HMPV protein shot for adults 60 and older
A single shot of a two-virus vaccine is being tested in adults 60+ to see if it can prevent RSV and hMPV infections compared with placebo.
-
Evaluating a new vaccine for Respiratory Syncytial Virus
This study is testing a new vaccine for Respiratory Syncytial Virus (RSV) in adults to see how safe it is and how well it helps the immune system.
-
Antiviral treatment for early RSV symptoms
This trial will test whether antiviral drugs—ribavirin, molnupiravir, or favipiravir—can lower viral levels and help adults 18–64 with early RSV recover faster than receiving no antiviral treatment.
-
Examining the impact of COVID-19 on RSV-related emergency visits in children
This study looks at how COVID-19 affected emergency visits for bronchiolitis and RSV in young children to see what might happen as restrictions ease.
-
RSV vaccine safety and immune response in lung transplant patients vs. healthy adults
This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.
-
RSV vaccine in children at high risk to see if it is safe and makes a strong immune response
This study tests whether the RSVpreF vaccine is safe and helps the immune system in children aged 5 to under 18 who are at high risk for RSV illness, including those who are immunocompromised.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.